SCHEMBL22490929

SCHEMBL22490929

O=C(CO[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.47
NR4A1 P22736 1/20 0.46
NR4A2 P43354 1/20 0.46
NR4A3 Q92570 1/20 0.46
PLA2G4B P0C869 1/20 0.44
MAOB P27338 2/20 0.44
EGFR P00533 4/20 0.44
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
SRD5A2 P31213 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
SLC5A1 P13866 1/20 0.42
SLC5A2 P31639 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HK1 P19367 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22490921 1.00 PARP10 (0.47) PARP10NR4A1NR4A2NR4A3PLA2G4B
SCHEMBL22490858 1.00 PARP10 (0.47) PARP10NR4A1NR4A2NR4A3PLA2G4B
SCHEMBL17912273 0.82 MAOB (0.51) MAOBSLC5A1SLC5A2
SCHEMBL22490851 0.82 MAOB (0.51) MAOBSLC5A1SLC5A2
SCHEMBL7694157 0.82 SLC5A2 (0.47) PARP10NR4A1NR4A2NR4A3MAOB
SCHEMBL22490933 0.81 PARP10 (0.49) PARP10NR4A1NR4A2NR4A3PLA2G4B
SCHEMBL22490875 0.81 PARP10 (0.49) PARP10NR4A1NR4A2NR4A3PLA2G4B
SCHEMBL22490915 0.81 PARP10 (0.49) PARP10NR4A1NR4A2NR4A3PLA2G4B
SCHEMBL5265599 0.79 SLC6A2 (0.56) SLC5A2
SCHEMBL4279552 0.79 SLC6A2 (0.56) SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed
EP-3717463-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 PARP10 1135/4885NR4A1 4102/4885NR4A2 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.